B-intervention	0	3	Low
I-intervention	3	4	-
I-intervention	4	13	molecular
I-intervention	13	14	-
I-intervention	14	20	weight
I-intervention	21	28	heparin
O	29	35	versus
B-control	36	43	placebo
O	44	47	for
O	48	51	the
O	52	62	prevention
O	63	65	of
B-condition	66	72	venous
I-condition	73	88	thromboembolism
O	89	91	in
O	92	102	metastatic
O	103	109	breast
O	110	116	cancer
O	117	119	or
O	120	125	stage
O	126	129	III
O	129	130	/
O	130	132	IV
O	133	137	lung
O	138	144	cancer
O	144	145	.

O	146	148	In
O	149	150	2
O	151	157	double
O	157	158	-
O	158	163	blind
O	164	171	studies
O	171	172	,
B-eligibility	173	183	ambulatory
I-eligibility	184	192	patients
I-eligibility	193	197	with
I-eligibility	198	209	objectively
I-eligibility	210	216	proven
I-eligibility	216	217	,
I-eligibility	218	230	disseminated
I-eligibility	231	241	metastatic
I-eligibility	242	248	breast
I-eligibility	249	258	carcinoma
I-eligibility	259	260	(
I-eligibility	260	265	TOPIC
I-eligibility	265	266	-
I-eligibility	266	267	1
I-eligibility	267	268	)
I-eligibility	269	271	or
I-eligibility	272	277	stage
I-eligibility	278	281	III
I-eligibility	281	282	/
I-eligibility	282	284	IV
I-eligibility	285	288	non
I-eligibility	288	289	-
I-eligibility	289	294	small
I-eligibility	294	295	-
I-eligibility	295	299	cell
I-eligibility	300	304	lung
I-eligibility	305	314	carcinoma
I-eligibility	315	316	(
I-eligibility	316	321	TOPIC
I-eligibility	321	322	-
I-eligibility	322	323	2
I-eligibility	323	324	)
O	325	329	were
O	330	340	randomized
O	341	343	to
O	344	354	certoparin
O	355	359	3000
O	360	362	IU
O	363	365	or
O	366	373	placebo
O	374	388	subcutaneously
O	389	393	once
O	394	399	daily
O	399	400	,
O	401	404	for
O	405	406	6
O	407	413	months
O	413	414	.

O	415	422	Primary
O	423	431	efficacy
O	432	439	outcome
O	440	443	was
B-outcome-Measure	444	455	objectively
I-outcome-Measure	456	465	confirmed
I-outcome-Measure	466	477	symptomatic
I-outcome-Measure	478	480	or
I-outcome-Measure	481	493	asymptomatic
I-outcome-Measure	494	500	venous
I-outcome-Measure	501	516	thromboembolism
I-outcome-Measure	517	518	(
I-outcome-Measure	518	521	VTE
I-outcome-Measure	521	522	)
O	522	523	.

O	524	530	Safety
O	531	539	outcomes
O	540	548	included
O	549	557	bleeding
O	558	559	(
O	559	564	major
O	565	568	and
O	569	574	minor
O	574	575	)
O	575	576	,
O	577	580	and
O	581	597	thrombocytopenia
O	597	598	.

O	599	604	TOPIC
O	604	605	-
O	605	606	1
O	607	610	was
O	611	617	halted
O	618	623	after
O	624	626	an
O	627	634	interim
O	635	643	analysis
O	643	644	.

B-outcome	645	651	Venous
I-outcome	652	667	thromboembolism
O	668	678	occurrence
O	679	682	was
O	683	686	not
O	687	696	different
O	697	704	between
O	705	714	treatment
O	715	721	groups
O	722	724	in
O	725	730	TOPIC
O	730	731	-
O	731	732	1
O	733	734	(
B-iv-bin-percent	734	735	4
I-iv-bin-percent	735	736	%
O	737	744	treated
O	745	749	with
O	750	760	certoparin
O	760	761	,
B-iv-bin-abs	762	763	7
O	764	766	of
B-intervention-participants	767	770	174
O	771	773	vs
B-cv-bin-percent	774	775	4
I-cv-bin-percent	775	776	%
O	777	786	receiving
O	787	794	placebo
O	794	795	,
B-cv-bin-abs	796	797	7
O	798	800	of
B-control-participants	801	804	177
O	804	805	,
O	806	810	odds
O	811	816	ratio
O	817	818	[
O	818	820	OR
O	820	821	]
O	822	823	1
O	823	824	.
O	824	826	02
O	826	827	;
O	828	830	95
O	830	831	%
O	832	842	confidence
O	843	851	interval
O	852	853	[
O	853	855	CI
O	855	856	]
O	857	858	0
O	858	859	.
O	859	861	30
O	861	862	-
O	862	863	3
O	863	864	.
O	864	866	48
O	866	867	)
O	868	871	and
O	872	874	in
O	875	880	TOPIC
O	880	881	-
O	881	882	2
O	883	884	(
B-iv-bin-percent	884	885	4
I-iv-bin-percent	885	886	.
I-iv-bin-percent	886	887	5
I-iv-bin-percent	887	888	%
O	888	889	,
B-iv-bin-abs	890	892	12
O	893	895	of
B-intervention-participants	896	899	268
O	899	900	)
O	901	903	vs
B-cv-bin-percent	904	905	8
I-cv-bin-percent	905	906	.
I-cv-bin-percent	906	907	3
I-cv-bin-percent	907	908	%
O	908	909	,
B-cv-bin-abs	910	912	22
O	913	915	of
B-control-participants	916	919	264
O	919	920	,
O	921	933	respectively
O	933	934	,
O	935	937	OR
O	938	939	0
O	939	940	.
O	940	942	52
O	942	943	;
O	944	946	CI
O	947	948	0
O	948	949	.
O	949	951	23
O	951	952	-
O	952	953	1
O	953	954	.
O	954	956	12
O	956	957	)
O	957	958	.

B-outcome	959	968	Mortality
O	969	972	was
O	973	976	not
O	977	986	different
O	987	994	between
O	995	1001	groups
O	1001	1002	.

O	1003	1004	A
O	1005	1009	post
O	1010	1013	hoc
O	1014	1022	analysis
O	1023	1029	showed
O	1030	1040	certoparin
O	1041	1054	significantly
O	1055	1062	reduced
B-outcome	1063	1066	VTE
O	1067	1069	in
O	1070	1075	stage
O	1076	1078	IV
O	1079	1083	lung
O	1084	1093	carcinoma
O	1094	1095	(
B-iv-bin-percent	1095	1096	3
I-iv-bin-percent	1096	1097	.
I-iv-bin-percent	1097	1098	5
I-iv-bin-percent	1098	1099	%
O	1100	1102	vs
B-cv-bin-percent	1103	1105	10
I-cv-bin-percent	1105	1106	.
I-cv-bin-percent	1106	1107	2
I-cv-bin-percent	1107	1108	%
O	1108	1109	;
O	1110	1111	P
O	1112	1113	=
O	1114	1115	.
O	1115	1118	032
O	1118	1119	)
O	1120	1127	without
O	1128	1137	increased
O	1138	1146	bleeding
O	1146	1147	.

O	1148	1150	In
O	1151	1161	conclusion
O	1161	1162	,
O	1163	1173	thrombosis
O	1174	1178	risk
O	1179	1182	and
O	1183	1195	prophylactic
O	1196	1203	benefit
O	1204	1207	was
O	1208	1215	highest
O	1216	1218	in
O	1219	1224	stage
O	1225	1227	IV
O	1228	1232	lung
O	1233	1242	carcinoma
O	1243	1251	patients
O	1251	1252	.
